Zhao Congling, Cai Chunyan, Ding Qiang, Dai Hongbin
Aier Eye Hospital of Wuhan university, Wuhan, Hubei Province, China.
Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
BMC Ophthalmol. 2020 Dec 7;20(1):478. doi: 10.1186/s12886-020-01746-w.
The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effectiveness of controlling the progression of myopia.
This work was done through the data searched from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of the included studies. In addition, a meta-analysis was performed using Revman5.3 software.
A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than that in the control group, with MD = - 0.80, 95% CI (- 0.94, - 0.66) during the whole observation period. There was a statistical difference among 0.05, 0.5, and 1.0% atropine (P = 0.004). In addition, less axial elongation was shown, with MD = - 0.26, 95% CI (- 0.33, - 0.18) during the whole observation period.
The effectiveness of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose.
阿托品延缓近视进展的效果及安全性已得到广泛研究，但其最佳剂量仍不明确。因此，本荟萃分析的目的是系统评价阿托品控制近视进展的安全性和有效性，并探讨阿托品剂量与控制近视进展效果之间的关系。
通过检索PubMed、MEDLINE、EMBASE和Cochrane对照试验中央注册库的数据开展本研究。还使用Cochrane手册评估纳入研究的质量。此外，使用Revman5.3软件进行荟萃分析。
共纳入10项随机对照试验（RCT）。在整个观察期内，阿托品治疗组的近视进展缓解程度大于对照组，MD = -0.80，95%CI（-0.94，-0.66）。0.05%、0.5%和1.0%阿托品之间存在统计学差异（P = 0.004）。此外，在整个观察期内，轴向伸长较少，MD = -0.26，95%CI（-0.33，-0.18）。
阿托品控制近视进展的有效性与剂量相关。0.05%阿托品可能是最佳剂量。
